Hepcivir 400mg Sofosbuvir
- BrandHepcivir 400mg Sofosbuvir
- Country of manufactureIndia
- Product NameHepcivir 400mg Sofosbuvir
- Product TypeTablets
- Strength400 mg
Exporter of Hepcivir 400mg Sofosbuvir
Sofosbuvir is a new drug candidate for hepatitis C treatment, with the chemical name L-Alanine, N-[[P(S),2′R]-2′-deoxy-2′-fluoro-2′-methyl-P-phenyl-5′-uridylyl]-, 1-methylethyl ester and a molecular formula of C22H29FN3O9P. Previously known as PS-7977 or GS-7977, it has shown promising results in numerous in vitro studies against all the genotypes of HCV. It is a nucleotide analog that is a highly potent inhibitor of the NS5B polymerase in HCV. This drug has shown high efficacy in combination with several other drugs with and without PEG-INF, against HCV. Sofosbuvir is of special interest among the directly acting antiviral drugs under development, due to its high potency, low side effects, oral administration, and high barrier to resistance.
Hepatitis C virus is a single-stranded RNA virus, and its open-reading frame encodes ten structural proteins (viral capsid and envelope) and non-structural proteins (required for viral replication). NS5B is one of the non-structural proteins essential for viral RNA replication, and has been found to be a valuable target for directly acting antiviral agents (DAAs). The uridine nucleotide analog sofosbuvir is a phosphoramidate prodrug that has to be triphosphorylated within the cells to produce its action. The required enzymes for its activation are present in the human hepatic cells, therefore, it is converted to its active metabolite during the first-pass metabolism, directly at the desired site of action: The liver. The metabolic pathway for activation of the prodrug[5,10] is shown in Figure 1. This analog then mimics the physiological nucleotide and competitively blocks the NS5B polymerase, thus inhibiting the HCV-RNA synthesis by RNA chain termination.[4,7] The catalytic site of the enzyme is also highly conserved across all the HCV genotypes, accounting for pan-genotypic efficacy of sofosbuvir.